Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Class A

Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Class A

SSZSE:301246
14.66
CNY
-0.16
(-1.08%)
0.76EPS
22.86P/E
7.02BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Class A carries a market capitalization of 7.02B, placing it among publicly traded companies globally. Its enterprise value stands at 6.00B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap7.02B
Enterprise Value6.00B

Share Statistics

As of September 30, 2026, Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Class A has 400.01M shares outstanding.

Shares Outstanding400.01M

Valuation Ratios

As of September 30, 2026, Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 22.86. The price-to-sales ratio is 2.71, and the price-to-book ratio stands at 1.51.

PE Ratio22.86
PS Ratio2.71
PB Ratio1.51
P/TBV Ratio1.57

Enterprise Valuation

As of September 30, 2026, Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Class A trades at an EV/EBITDA multiple of 14.81 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.34 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 14.81 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 6.00B versus a market cap of 7.02B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales2.34
EV / EBITDA14.81
EV / EBIT14.81

Financial Position

As of September 30, 2026, Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Class A maintains a current ratio of 2.56, meaning it holds 2.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 14.36, indicating elevated leverage, while an interest coverage ratio of 26.51 demonstrates strong ability to service its debt obligations.

Current Ratio2.56
Quick Ratio1.35
Debt / Equity14.36
Debt / EBITDA1.64
Interest Coverage26.51

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 1.14M in revenue per employee across its workforce of 2,258.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee1.14M
Employee Count2,258.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Class A recorded 72.24M in income tax expense. That works out to an effective tax rate of 19.27, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 374.96M, leaving 304.39M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax72.24M
Effective Tax Rate19.27

Stock Price Statistics

CNY

As of the close on November 17, 2026, Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Class A's stock has declined approximately 31.46% over the past 52 weeks. The 50-day moving average sits at 16.73, while the 200-day moving average is 22.16.

52-Week Price Change-31.46%
50-Day Moving Average16.73
200-Day Moving Average22.16

Income Statement

CNY

Over the twelve months ended September 30, 2026, Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Class A generated 2.56B in revenue and converted that into 304.39M in net income, yielding earnings per share of 0.76. EBITDA reached 405.16M, while operating income came in at 365.15M.

Revenue2.56B
Gross Profit579.18M
Operating Income365.15M
Pretax Income374.96M
Net Income304.39M
EBITDA405.16M
EBIT405.16M
Earnings Per Share (EPS)0.76

Balance Sheet

CNY

As of September 30, 2026, Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Class A holds 1.68B in cash and equivalents against 666.04M in total debt, resulting in a net debt position of -103.59M. Total book value stands at 4.64B, with working capital of 1.94B providing operational flexibility.

Cash & Cash Equivalents1.68B
Total Debt666.04M
Net Debt-103.59M
Equity (Book Value)4.64B
Book Value Per Share11.60
Working Capital1.94B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-258.38M

Margins

Over the twelve months ended September 30, 2026, Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Class A posted a gross margin of 22.59, reflecting its pricing power and cost economics. The operating margin of 14.24 and net profit margin of 11.87 provide insight into operational efficiency.

Gross Margin22.59
Operating Margin14.24
Pretax Margin14.63
Profit Margin11.87
EBITDA Margin15.80

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Class A paid dividends of 0.09 per share. The dividend payout ratio of 12.12 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 1.36, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Class A shareholders.

Dividend Per Share0.09
Payout Ratio12.12
Shareholder Yield1.36

Scores

As of September 30, 2026, Hubei Hongyuan Pharmaceutical Technology Co., Ltd. Class A has an Altman Z-Score of 3.73, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.73